The FDA has granted breakthrough therapy status to maribavir (maribavir) for the treatment of cytomegalovirus, herpes beta virus infection in immunocompromised patients, including organ or stem cell transplant recipients.
It is indicated for the prevention and treatment of human cytomegalovirus disease in organ or stem cell transplant recipients who are resistant or refractory to previous treatment with ganciclovir, valganciclovir, cidofovir or foscarnet.